1. Bupropion and/or naltrexone are not associated with increased risk of major adverse cardiovascular events: A network meta-analysis of additive effects. (December 2020) Authors: De Carvalho, L.S.F.; Luchiari, B.M.; Bonilha, I.; Sposito, A. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IDF21-0298 Glucose-lowering and the risk of MACE with novel antidiabetic therapies: A systematic review and meta-analysis. (April 2022) Authors: Luchiari, B.; Carvalho, L.S.; Nogueira, A.C.; Cintra, R.; Bonilha, I.; Barreto, J.; Benchimol, A.; Couri, C.E.; Borges, J.L.; Sposito, A. Journal: Diabetes research and clinical practice Issue: Volume 186:Supplement 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ischemic postconditioning with HDL preserves mitochondrial complex I activity. (December 2020) Authors: Bonilha, I.; Barreto, J.; Carmo, H. Do; Busanello, E.; Marques, A.C.; Virginio, V.; Petrucci, O.; Vercesi, A.E.; Sposito, A. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗